[{"orgOrder":0,"company":"Intravacc","sponsor":"Dutch Leiden University Medical Center","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"NETHERLANDS","productType":"Vaccine","year":"2022","type":"Partnership","leadProduct":"Nanovac","moa":"SARS-CoV-2 S","graph1":"Infections and Infectious Diseases","graph2":"Phase I\/ Phase II","graph3":"Intravacc","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Nasal Spray","sponsorNew":"Intravacc \/ Dutch Leiden University Medical Center","highestDevelopmentStatusID":"7","companyTruncated":"Intravacc \/ Dutch Leiden University Medical Center"},{"orgOrder":0,"company":"ISA Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"NETHERLANDS","productType":"Vaccine","year":"2023","type":"Inapplicable","leadProduct":"ISA104","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase I\/ Phase II","graph3":"ISA Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"ISA Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"ISA Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"ISA Pharmaceuticals","sponsor":"Health Holland","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"NETHERLANDS","productType":"Vaccine","year":"2021","type":"Partnership","leadProduct":"ISA104","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase I\/ Phase II","graph3":"ISA Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"ISA Pharmaceuticals \/ Health Holland","highestDevelopmentStatusID":"7","companyTruncated":"ISA Pharmaceuticals \/ Health Holland"}]

Find Clinical Drug Development Pipelines & Deals | PipelineProspector

Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          Pharmex
                          Not Confirmed
                          Pharmex
                          Not Confirmed

                          Details : ISA104 is designed to developed using Synthetic Long Peptide (SLP®) technology and create a strong and specific immune response against HBV, with the aim to functionally cure chronically infected patients.

                          Product Name : ISA104

                          Product Type : Vaccine

                          Upfront Cash : Inapplicable

                          August 31, 2023

                          Lead Product(s) : ISA104

                          Therapeutic Area : Infections and Infectious Diseases

                          Highest Development Status : Phase I/ Phase II

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          02

                          Pharmex
                          Not Confirmed
                          Pharmex
                          Not Confirmed

                          Details : This new vaccine, NANOVAC, is based on microscopic soluble nano-spheres, containing synthetic mini proteins that, when administered as a nasal spray, directly protects the upper respiratory tract including nasal passages and throat (mucosa) before the vi...

                          Product Name : Nanovac

                          Product Type : Vaccine

                          Upfront Cash : Undisclosed

                          May 01, 2022

                          Lead Product(s) : Nanovac

                          Therapeutic Area : Infections and Infectious Diseases

                          Highest Development Status : Phase I/ Phase II

                          Sponsor : Dutch Leiden University Medical Center

                          Deal Size : Undisclosed

                          Deal Type : Partnership

                          blank

                          03

                          Pharmex
                          Not Confirmed
                          Pharmex
                          Not Confirmed

                          Details : Under the collaboration, Halix will utilise its brand new state-of-the-art GMP facilities with capacity up to 1,000 L SUB scale, supporting the manufacture of ChAdOx1 nCoV-19 clinical trial material.

                          Product Name : AZD1222

                          Product Type : Vaccine

                          Upfront Cash : Undisclosed

                          April 15, 2020

                          Lead Product(s) : ChAdOx1 nCoV-19

                          Therapeutic Area : Infections and Infectious Diseases

                          Highest Development Status : Phase I/ Phase II

                          Sponsor : University’S Jenner Institute

                          Deal Size : Undisclosed

                          Deal Type : Collaboration

                          blank